We evaluated the predictive value of baseline HIV-1 genotypic resistance mutations for failure of a nucleoside reverse transcriptase inhibitor (NRTI) containing therapy. The change in therapy of 88 HIV-1-infected patients was analyzed retrospectively, relating the genotypic resistance profile at baseline to the evolution of viral load and CD4 1 T cell counts. Genotypic resistance at baseline and at 6 months was evaluated with the LiPA HIV-1 RT, which detects mutations at codons 41, 69, 70, 74, 184, and 215. At 1 to 3 months after change in therapy, patients without preexisting resistance mutations to the new drug (group S) had a significantly better evolution in viral load (reduction of 0.37 log 10 ) compared with patients with known preexisting resistance mutation(s) (group R) (increase of 0.08 log 10 ). This difference was particularly striking for patients with the baseline M184V mutation and whose treatment was modified by the addition of lamivudine. After 6 months the median difference in viral load evolution between the two groups increased to 0.61 log 10 : the viral load of patients of group S was still 0.18 log 10 below baseline while patients of group R had an increase of 0.43 log 10 in viral load above baseline. Changes in CD4
INTRODUCTION
T H E EM ER G EN CE O F HIV-1 drug resistance correlates with the presence of point mutations in the targeted protein. [1] [2] [3] [4] [5] The relationship between the presence of point mutations and phenotypic resistance is continuously being mapped but not entirely understood. 6 Even though the extent to which resistant viruses contribute to treatment failure is uncertain, a strong association has been suggested betw een the emergence of resistant viruses and clinical deterioration, increase in viral load, and decrease in CD4 1 T cell count. 5,7 -11 It is evident that besides the developm ent of resistance-related mutations, other factors can also account for a poor clinical outcome, including host-related factors such as drug adherence or drug absorption, and virus-related factors such as syncytium-induc ing/non-syncytium -inducing phenotype and virus dynam ics. 12 Although potent combination therapies may be able to delay the emergence of drug-resistant virus, it is still unclear whether com bination therapy will postpone resistance indefinitely. 13 Despite encouraging results of highly active antiretroviral therapy (HAART) in suppression of virus replication for more than 30 months, reports have shown ongoing virus replication in lymph nodes [14] [15] [16] [17] and viruses with resistance-related mutations have already been isolated from patients receiving HAART. 18 Currently the best markers for efficacy or failure of therapy remain the clinical inform ation, the CD4 1 T cell count, and especially the plasma viral load. 19 As the number of drugs available to treat HIV infection increases, patients are able to switch from one therapy to another, in general avoiding the use of drugs that are part of a failing regimen because of the possibility of drug resistance. In case of treatment failure, the resistance profile at the moment of changing therapy is potentially important to guide the decision on what drugs to change to, since there is considerable cross-resistance between drugs of the same class. Further evaluation is needed to establish the role of resistance testing in the individual patient follow-up and to determine if guidance of therapy using the results of resistance testing is able to change the disease progression.
Nucleoside analog reverse transcriptase inhibitors (NRTIs) were the first antiretroviral drug used in clinical practice and they are actually the most widely prescribed class of antiretroviral drugs, as part of combination therapies. Because of their importance in the clinical setting and because of the availability of samples from patients switching nucleoside analogs, we specifically wanted to focus on NRTIs in the study presented here.
It has been show n that resistance-related mutations appear first as minor variants, which take over the virus population when drug-selective pressure is maintained. 4, 20 The only presently available genotypic assay for resistance to nucleoside analog that can measure minor (down to 5%) resistant variants is the HIV-1 reverse transcriptase (RT) line probe assay (INNOLiPA HIV-1 RT, Innogenetics, Ghent, Belgium). LiPA HIV-1 RT can detect a selected number of resistance mutations: M41L, T69D, K70R, L74V, M184V, and T215F/Y. 21 We performed a retrospective analysis of the change of therapy in 88 HIV-1-infected patients, treated solely with nucleoside analogs. By measuring baseline genotypic resistance to the newly added drug, we tried to establish the predictive value of genotyping, in this case INNO-LiPA HIV-1 RT, on the evolution of CD4 1 cell counts and viral loads.
MATERIALS AND METHODS

Patient population and study design
We sampled 107 HIV-1-infecte d patients from 3 European countries (Belgium, Spain, and Luxembourg), starting or changing a single drug of a treatment consisting solely of nucleoside reverse transcriptase inhibitors. Genotypic resistance to nucleoside analogs was evaluated at baseline and at 6 months with the line probe assay (INNO-LiPA HIV-1 RT, Innogenetics), which is able to detect minor populations, in some cases down to 1%. 21 In particular, the follow ing mutations in the RT gene were scored: for didanosine, positions 74 and 184; for zalcitabine, positions 69, 74, and 184; for lamivudine, position 184; and for zidovudine, positions 41, 70, and 215. Since no resistance-related mutations for stavudine can be analyzed with the HIV-1 RT LiPA, no patients were included who received stavudine as a newly added drug. Clinical information, therapy history, CD4 1 T cell counts, and viral loads at baseline (the moment of therapy change), 1-3 months after the change of therapy and 6 months after the change of therapy, were provided by the participating centers. 
CD4
LiPA test performance
Genotypic resistance was determined with INNO-LiPA HIV-1 RT polymerase chain reaction (PCR) prim ers and hybridization strips in the participating centers according to the manufacturer recomm endations. 21 All strips were collected in Leuven and correct scoring was confirmed. The presence of resistance mutations (either as mixture or as pure mutant) was scored.
Statistical analysis
Comparisons between the patients with and without baseline resistance mutations with regard to CD4 1 cell count and log viral load at baseline, and evolution of CD4 
RESULTS
Analysis of baseline samples for resistance to newly added drugs
Samples from 107 patients changing or adding 1 nucleoside analog RT inhibitor were collected for evaluation of the genotype at baseline, using the INNO-LiPA HIV-1 RT. Fourteen patients were excluded because of the absence of amplification and 5 samples gave absence of hybridization of the codon of interest according to the added drug. The general characteristics and the treatment changes of the remaining 88 HIV-1-infected patients are summarized in Tables 1 and 2 . The baseline
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nucleoside treatment represents the most recent antiretroviral treatment of the included patients; for the majority of the patients, this is the com plete treatment history. For patients with baseline resistance mutations (either mixtures or pure mutants) against the added drug, the resistance profile at baseline is given in Table 3 . Of the 88 patients with interpretable baseline resistance profiles, 68% carried resistance-related mutations detectable by LiPA; however 76 patients had no preexisting mutations against the newly added drug and 12 had preexisting mutation(s) against the newly added drug: 4 for zidovudine, 2 for didanosine, 1 for zalcitabine, and 5 for lamivudine ( Table   3) . None of the patients with baseline resistance mutations against zidovudine displayed the L74V or M184V mutation, both of which are known to antagonize the resistance to zidovudine. 22, 23 In our study population, baseline resistance to lamivudine can be explained by cross-resistance due to previous use of didanosine or zalcitabine (patients 8, 9, 10, 11, and 12). One patient with baseline resistance to didanosine had lamivudine experience in a previous treatment regimen (patient 5). The second patient with baseline resistance to didanosine had already been treated with didanosine and lamivudine (patient 6). Two cases of baseline resistance to zidovudine are ex-BASELINE HIV-1 GENOTYPIC RESISTANCE 531 
Abbreviations: AZT, zidovudine; ddI, didanosine; ddC, zalcitabine; 3TC, lamivudine. a The newly added drug is indicated in italics. The newly added drug and the preexisting resistance mutation(s) against the newly added drug are indicated in italics.
plained by zidovudine experience in a previous treatment regimen (patients 3 and 4). The presence of the K70R mutation in patients 1 and 2 can be due either to the transmission of zidovudine-resistant virus, or to the presence of K70R as a naturally occurring polymorphism as has been reported. 24 Since no information is available about the respective donors (genotype and treatment history), we can only speculate about this. The patient with baseline resistance to zalcitabine had only previous zidovudine experience (patient 7). In 6 of 12 patients with baseline resistance, baseline resistance mutations were present as a mixture with the wild-type sequence. After 6 months, INNO-LiPA HIV-1 RT data were available only for five of these six patients, with three of them developing a pure mutant population at the respective sites under the selective pressure of the newly added drug.
Evolution of viral load and CD4
1 cell count in patients with and without baseline resistance mutation(s)
The evolution of viral load and CD4 1 count at 1-3 months (median, 90 days) and 6 months after changing therapy was com pared between patients without (n 5 76; group S) and with (n 5 12; group R) mutation(s) against the newly added drug, using the Wilcoxon test. Since different viral load assays were used in the different centers, evolutions in viral load rather than absolute values were compared. The evolution in viral load between patients in group S and group R was significantly different ( Fig. 1 and Table 3 ). One to 3 months after changing therapy, the viral load of group S decreased by 0.37 log 10 (median), while the viral load of group R increased by 0.08 log 10 (median) (p 5 0.004). Six months after changing therapy, the difference in the evolution of the viral load in the two groups had even increased to 0.61 log 10 (p 5 0.009): patients without preexisting resistance mutations to the new drug still had a reduction in viral load of 0.18 log 10 below baseline, while patients with known preexisting resistance mutation(s) had an increase of 0.43 log 10 in viral load above baseline. After 3 months, both groups showed a rising viral load, suggesting only a transient benefit of the single added drug, even in the absence of preexisting mutations.
Evolution of CD4
1 cell count did not show any significant difference between the two groups, S and R; both groups showed a rise in CD4 1 cell count during follow-up (Table 3) . Group S showed a median increase (25th percentile; 75th percentile) in CD4 
Presence of baseline resistance mutations in responders versus nonresponde rs
Responders were defined as patients having a decrease of 0.5 log 10 or more in viral load 1 to 3 months after starting or changing therapy, since a reduction of the viral load of 0.5 log 10 is reported to provide clinical benefit 19 and adding or starting one NRTI gives only a modest drop in viral load. 13 Among patients who were responding (n 5 32), 3% (1 patient with baseline resistance to zalcitabine) had baseline resistance mutations against the added drug, while among patients who were not re-BASELINE HIV-1 GENOTYPIC RESISTANCE 533
FIG. 1.
Evolution of viral load after therapy is changed to include a newly added nucleoside analog reverse transcriptase inhibitor. The relative change in viral load (in log HIV RNA copies per milliliter) is given as a function of time since the change in therapy. The patient groups without (group S) and with (group R) baseline resistance against the new ly added drug are indicated. Patient group S is com pared with group R; p , 0.05 is considered significant. General baseline characteristics of groups S and R are given in Table 1 , the change in treatment is given in Table 2 , and the resistance profile of the patients from group R is given in Table 3 .
sponding (n 5 56) 20% (n 5 11) had baseline resistance mutations. This difference is significant (p 5 0.025). The positive predictive value of baseline resistance for the lack of response in our group of patients was 92%, and the negative predictive value of absence of baseline resistance for response to the change of therapy was 41%.
Analysis of the evolution of the resistance pattern according to the drug received
Of 88 patients changing or adding 1 nucleoside analog RT inhibitor, 86 patients were evaluated for genotypic resistance with the INNO-LiPA HIV-1 RT at baseline and at 6 months. Two patients were excluded because of the absence of amplification, one of which was the patient with baseline resistance mutation against zalcitabine (patient 7 in Table 3 ). In our patient population, zidovudine and lam ivudine resistance mutations occurred with a much higher frequency (88 and 94.5% in experienced patients, respectively) than didanosine and zalcitabine resistance mutations (22 and 15% , respectively). However, because of the addition of lamivudine, 37% of patients that had didanosine, and 38% of patients that had zalcitabine, included in their regimen developed the M184V mutation during this follow-up period, and are thus probably partially crossresistant to lamivudine and, respectively, didanosine and zalcitabine. On the other hand, zidovudine resistance in experienced patients was probably partially antagonized in 4% by the L74V mutation, and in 27% by the M184V mutation, due to the com bination of zidovudine with lamivudine, didanosine, or zalcitabine (data not shown).
Predictive value of each resistance-related mutation for viral load evolution
Because of the small number of patients for each baseline resistance mutation, we investigated only the separate predictive value of the M184V mutation found in five patients adding lamivudine. The evolution of the viral load for these 5 patients (patients 8, 9, 10, 11, and 12 in Table 3 ) was compared with the evolution of the viral load of the remaining 28 patients without baseline resistance, who were adding lamivudine. One to 3 months after baseline, the patients without baseline resistance to lamivudine had a decrease in viral load of 0.5 log 10 , while the five patients with baseline resistance were doing significantly worse; they had an increase of 0.68 log 10 (p 5 0.005). Six months after baseline, the viral load was increasing in both groups, the patients without baseline resistance remained 0.05 log 10 under the baseline level, while the 5 patients with baseline resistance had an increase in viral load of 1.12 log 10 above baseline (p 5 0.002). The rise in viral load at 6 months was most probably due to the development of the M184V mutation in 26 of the 28 patients without baseline resistance to lamivudine (3TC).
DISCUSSION
Among the available assays for drug resistance testing, genotypic assays (detection of drug resistance mutations) give faster results and obviate the need to work with infectious material, but they can be used only for known resistance-related mutations and known interactions between mutations. DNA sequencing methods applied to PCR populations are able to score mutations at any position in the target gene, but are generally able to detect variants only if they are present as more than 25% of the population. 20, 25 The INNO-LiPA HIV-1 RT can score only a particular set of mutations, but is able to detect minor variants in a virus population at some positions down to 1%. 20, 21 Although phenotypic assays are not biased by unknown resistance mutations and their interactions, they give a drug sensitivity pattern according to the predom inant variant in a virus population. 20 Therefore phenotypic assays may fail to detect evolving resistance that has not yet led to measurable increases in the 50% inhibitory concentration (IC 50 ). 12, 20, 26 We investigated the baseline genotypic resistance to a newly added nucleoside reverse transcriptase inhibitor of patients changing therapy consisting solely of NRTIs. To analyze the value of genotyping at baseline in predicting the evolution of viral load and CD4
1 cell count on change of therapy, we were interested in detecting the presence of resistance-related mutations even when present as minor variants since the outgrowth of minor variants with resistance-related mutations can be expected under the selective pressure of the corresponding drugs. The INNO-LiPA HIV-1 RT was used because of its ability to detect multiple codon changes of interest in a single test and its high sensitivity in detecting mixtures. The development of dominant mutant genotypes with increased drug pressure was observed in three patients with baseline resistance. Not all mutations in a patient's HIV strain are relevant for the development of resistance. Even for the resistance-related mutations, not all of them are equally important. Although data seem to indicate that for zidovudine resistance the T215Y/F mutation is one of the key mutations, 27 no study has so far investigated the relevance of each individual resistance mutation. In the study presented here, we could not draw conclusions for each separate mutation because of the limited observations. Therefore we included in our analysis all known resistance-related mutations that can be scored by the INNO-LiPA HIV-1 RT. Other relevant mutations, such as the multinucleoside resistance patterns (the Q151M resistance pattern, 28 inserts at positions 68-70 in the reverse transcriptase 29 ), and NRTI-related mutations (K65R, D67G, L210W , and K219Q/E 1 ), can also influence drug response and should therefore be included in fast genotypic assays. The multi-nucleosid e resistance patterns have a low prevalence in multinucleoside-experienced patients, 0.5 to 2%, and are absent in patients with no or single nucleoside experience. [30] [31] [32] The lack of information on some of the other relevant nucleoside analog-related mutations only emphasizes the fact that our results are already highly significant, even without considering these additional mutations. The role of the G333D/E mutation, playing a role in dual resistance to zidovudine and 3TC, as well as the G196E mutation, 33 involved in didanosine resistance, needs further investigation. A limitation of all amplification-ba sed assays is the incomplete results due to the absence of amplification, occurring in this study in 13% . Another 4% of patients was excluded because of the absence of hybridization.
Of the 88 patients with interpretable baseline genotypes, 12 patients displayed preexisting resistance mutations against the added drug. None of the patients with baseline resistance mutations VAN VAERENBERGH ET AL.
against zidovudine displayed the L74V or M184V mutation, both of which are known to antagonize the resistance to zidovudine. 22, 23 Furthermore, by analyzing the genotypes of the samples of 11 of these 12 patients 6 months after changing therapy, all these patients maintained resistance-related mutations in a mixture or developed a pure mutant against the newly added drug.
The evolution of the viral load in the group of patients without baseline resistance mutations was significantly better than in the 12 patients with baseline resistance mutations, although the benefit from the change of therapy was only transient in both groups. The evolution of the CD4 1 T cell counts did not show any significant difference, possibly because of the transient benefit of the new therapy and the large variation in CD4 1 T cell counts compared with the limited number of patients studied here.
The significant higher drop in viral load of patients of group S was not due to the higher baseline viral load compared with group R (data not shown). Since it is known that the peak drop in viral load in response to NRTIs is related to baseline viral load, 34 we verified this in our data, by analyzing the viral load evolution in a subgroup of patients of group S having a baseline viral load equal to group R. This subpopulation still showed a significant different evolution in viral load compared with group R.
The rather small differences (maximum, 0.61 log 10 RNA copies/ ml) in evolution between the patients with and without baseline resistance mutations against the new ly added drug, are explained by the fact that adding or starting one NRTI in general gives a modest peak drop of 0.3 to 1.3 log 10 copies RNA/ml, depending on the drug and the start conditions. 13 Since these therapies are not able to inhibit completely virus replication, a loss of susceptibility to the drugs used could be expected during the follow-up period, owing to developing resistance. In our patient population this is reflected by an increase in viral load from 3 months on, both in patients with and without baseline resistance mutations, and by the accumulation of resistance-related mutations to the received drugs in both groups.
Since therapy change consisted of adding or changing only one NRTI, the criterion of response (decrease of 0.5 log 10 ) was difficult to fulfill in this study population, which explains the high number of nonresponders compared with responders even in the group without baseline resistance mutations. As previously reported for patients treated with protease inhibitors, 35 our results suggest that also for therapy with NRTIs, baseline resistance is an important predictor of therapy failure (positive predictive value of 91.6%). However, the absence of baseline resistance is not predictive of response to therapy (low negative predictive value). 36 This low negative predictive value in our study reflects the fact that we are considering only baseline resistance patterns, independent of drug experience. When a drug was part of a failing regim en before, it should not be used again as long as there remain other treatm ent options, since previous resistance mutations might still be present in a latent reservoir. It is important for the success of a new therapy that a patient has a wild-type genotype relative to the new drugs, but in patient follow-up factors such as previous drug history and drug adherence, which were not evaluated in this study, will also determine the choice and efficacy of a new therapy.
We also found that the M184V baseline resistance mutation significantly impaired therapy response to lamivudine. However, since this observation concerns only five patients, caution is needed until these results can be confirmed by others. Not enough data were available to draw conclusions about the other mutations separately. To investigate the predictive value of the other resistance-related mutations separately, a large number of observations would be necessary. Especially since, compared with the M184V mutation, which is known to confer important phenotypic resistance to lamivudine, the level of associated phenotypic resistance of the other mutations for their respective drugs (as the L74V mutation for didanosine [ddI] ) is more moderate. 1 The results of the first prospective trials, the VIRADAPT study 37 and the GART study, 38 have become available. Both trials showed a better virologic response in patients failing HAART when therapy was adapted on the basis both of genotype and the standard of care, compared with patients with a therapy change based on the standard of care. Follow -up periods were 12 and 3 months, respectively.
Although limited to a small number of patients with baseline resistance mutations to the newly added drug, our data suggest that baseline resistance mutations to NRTIs have a negative influence on the evolution of viral load even if present only as minor variant. It might thus be important to be able to detect minor mutant variants in a virus population, although this needs further investigation. In conclusion, although genotypic resistance testing has its limitations, we believe that the availability of new rapid assays for genotypic drug resistance testing can contribute to the increased use of individual resistance monitoring as a tool in therapy decisions at the start of antiviral therapy and at the moment of changing therapy. Defining ultimately the clinical role of resistance testing will need more prospective clinical trials that integrate the results of resistance assays in the therapeutical guidance of patients in order to determine if the application of these assays, together with the subsequent therapeutic actions, are able to influence the clinical outcome.
